Skip to main content
Signal8
Launch Terminal

Atara Biotherapeutics, Inc. (ATRA)

Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

NASDAQ:ATRAHealthcare
-6.10%$8.01
AH$8.01+0.00%vs close
Mkt Cap$81.24M
Float5.15M
O/S10.14M
Vol
$ Vol
RVOL
Inst Own44.1%
SI6.8%
Earnings
Dilution
Atara Biotherapeutics, Inc. logoNASDAQ:ATRA$8.01-6.10%
Upcoming Catalysts
  • Tabelecleucel (Tab-cel)PDUFA
    EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD) after at least one prior therapy
    Cash runway at this date: < 1 mo
    Mar 31, 2027in 149 daysPR
Phase Distribution
8 lead-sponsored trials·0 active·2 completed
Phase 12
Phase 1/23
Phase 21
Not applicable2
(3 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Completed

    Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

    EBV-specific T cells (EBV-CTLs)

    EBV-induced Lymphomas, EBV-associated Malignancies +1

    Enrollment
    87
    Start
    Dec 2011
    Primary Completion
    Jul 2019
    Completion
    Jul 2019
    NCT01498484
  • Phase 1/2
    Completed

    Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

    Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)

    EBV-induced Lymphomas, EBV-associated Malignancies +1

    Enrollment
    58
    Start
    Mar 1995
    Primary Completion
    Jul 2019
    Completion
    Jul 2019
    NCT00002663
  • Phase 1/2
    Terminated

    Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

    ATA188, Placebo

    Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

    Enrollment
    134
    Start
    Oct 2017
    Primary Completion
    Nov 2023
    Completion
    Jan 2024
    NCT03283826
  • Phase 1/2
    Terminated

    Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

    Tabelecleucel, Pembrolizumab

    Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms +3

    Enrollment
    12
    Start
    Feb 2019
    Primary Completion
    Aug 2021
    Completion
    Aug 2021
    NCT03769467
  • Phase 1
    Terminated

    A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    ATA3219

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    Enrollment
    1
    Start
    Sep 2024
    Primary Completion
    Mar 2025
    Completion
    Mar 2025
    NCT06256484
  • Phase 1
    Withdrawn

    A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

    ATA3219

    Lupus Nephritis, Systemic Lupus Erythematosus

    Enrollment
    0
    Start
    Apr 2025
    Primary Completion
    Apr 2025
    Completion
    Apr 2025
    NCT06429800
  • Expanded access
    No longer available

    Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

    tabelecleucel

    Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders +10

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT02822495
  • Expanded access
    No longer available

    Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

    Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)

    CMV Viremia, CMV Disease

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT03010332
Search ClinicalTrials.gov for “Atara Biotherapeutics”